SPTX

Peers: ANRO AXSM LBRX ACAD CMPS PRAX RAPP SUPN ALKS ABOS

| Held by: VTI IWM VXF PSIL IWO VTWO SCHA SBIO IWN IWC

Index	RUT
Market Cap	1.05B
Enterprise Value	780.91M
Income	-
Sales	-
Book/sh	7.89
Cash/sh	5.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	May 01, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.48
P/C	3.84
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.00
Current Ratio	18.00
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.54
EPS next Q	-0.57
EPS this Y	86.22%
EPS next Y	41.49%
EPS next 5Y	56.30%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 03 BMO
EPS/Sales Surpr.	-186.91% -

Insider Own	74.22%
Insider Trans	2.88%
Inst Own	31.04%
Inst Trans	83.65%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.10%
SMA50	-7.37%
SMA200	-2.63%
Trades

Shs Outstand	53.53M
Shs Float	13.80M
Short Float	26.95%
Short Ratio	17.86
Short Interest	3.72M
52W High	28.38 -30.95%
52W Low	14.85 31.99%
Volatility	7.98% 7.52%
ATR (14)	1.56
RSI (14)	48.67
Beta	-
Rel Volume	0.00
Avg Volume	208.25K
Volume	0

Perf Week	-4.90%
Perf Month	3.43%
Perf Quarter	-5.08%
Perf Half Y	-1.21%
Perf YTD	-6.67%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.22
Target Price	37.00
Prev Close	19.60
Price	19.60
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$37.00

Implied Upside

+88.8%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 14, 2026	Initiated	CCanaccord Genuity	Buy	$28	+42.9%
Sep 25, 2026	Initiated	RRaymond James	Strong Buy	$46	+134.7%
Jul 15, 2026	Initiated	HH.C. Wainwright	Buy	$50	+155.1%
May 26, 2026	Initiated	SStifel	Buy	$30	+53.1%
May 26, 2026	Initiated	LLeerink Partners	Outperform	$35	+78.6%
May 26, 2026	Initiated	JJP Morgan	Overweight	$42	+114.3%
May 26, 2026	Initiated	CCitigroup	Buy	$35	+78.6%

Today 06:00AM	Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Oct-28-26 07:00AM	Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference (Business Wire)
Oct-09-26 01:00PM	PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress (Business Wire)
07:00AM	Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress (Business Wire)
Oct-07-26 01:00PM	PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder and Sleep Disturbance (Business Wire)
07:00AM	Loading…
07:00AM	Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance (Business Wire)
Sep-22-26 03:00PM	PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ... (GuruFocus.com) +6.01%
Sep-14-26 07:00AM	Seaport Therapeutics to Participate in September Investor Conferences (Business Wire) +5.83%
Sep-09-26 01:13PM	PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers (Business Wire) -9.60%
07:00AM	Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers (Business Wire)
Aug-31-26 07:00AM	Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference (Business Wire)
Aug-26-26 09:41AM	Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls (The Fly) +12.12%
Aug-03-26 07:00AM	Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
Jun-09-26 02:00AM	PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire) +9.01%
Jun-08-26 07:00AM	Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (Business Wire)
07:00AM	Loading…
Jun-01-26 07:00AM	Seaport Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) -5.83%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOMBACH ROBERT J.	Director	Jun 22 '26	Buy	18.14	13,000	235,768	13,000	Jun 24 06:05 AM
ARCH Venture Partners XII, LLC	10% Owner	May 04 '26	Buy	18.00	1,100,000	19,800,000	6,294,951	May 04 06:02 PM

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.

Founder & Non-Employee Chair of the BoardDr. Steven M. Paul M.D.

FounderMs. Daphne Zohar

Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen Ph.D.

Chief Medical Officer & President of Clinical DevelopmentDr. Antony Loebel M.D.

Chief Financial OfficerMs. Lauren A. White M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Seaport Therapeutics Inc

Upgrade your Finviz experience